Cogent Biosciences (COGT)

Executive Summary

Cogent Biosciences is a publicly traded biotechnology company focused on developing precision therapies for genetically defined diseases, with a strong emphasis on targeting KIT D816V mutations in systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST), as well as FGFR2/3 and HER2 alterations in solid tumors. The lead asset, bezuclastinib, is a potent and selective KIT D816V inhibitor that has demonstrated encouraging clinical activity in advanced systemic mastocytosis (AdvSM) and is being evaluated in multiple Phase 2 trials, including a combination study with sunitinib in GIST. Additionally, early-stage pipeline candidates CGT4859 (FGFR2/3 inhibitor) and CGT4255 (HER2 inhibitor) address underserved patient populations with relevant genetic alterations. With multiple ongoing clinical trials across solid tumors and mastocytosis, Cogent aims to leverage validated biology to deliver novel treatment options. The company's clinical-stage portfolio and focus on genetically defined patient subsets position it for potential value inflection points over the next 12-18 months.

Upcoming Catalysts (preview)

• Q3 2026Bezuclastinib Phase 2 data in Advanced Systemic Mastocytosis (APEX trial, NCT04996875)70% success
• H2 2026Bezuclastinib + sunitinib Phase 2 interim data in GIST (NCT06208748)60% success
• H1 2027CGT4859 Phase 1/2 interim data in FGFR2/3-altered solid tumors (NCT06777316)50% success